Vascular Endothelial Growth Factor (VEGF) Antibodies Market Fundamentals 2019 – 2026 | Leading Companies, Revenue, Size, Demand Status and Growth Analysis Report
Global Vascular Endothelial Growth Factor (VEGF) Antibodies Market
Vascular Endothelial Growth Factor (VEGF) is a signal protein that helps in the formation of new blood vessels through a process, known as angiogenesis. Vascular endothelial growth factor is a part of several pathological processes and researches are often carried out for the development of novel therapies using these factors for diseases such as cancer. Normal functions of vascular endothelial growth factor includes embryonic development, formation of new blood vessels, and as a bypass for a blocked vessel.
To understand Research Methodology, please click https://www.coherentmarketinsights.com/ongoing-insight/vascular-endothelial-growth-factor-antibodies-market-1614
However, the overexpression of VEGF often culminates in fatal diseases, such as cancer. As solid tumors require additional blood supply in order to keep functioning, the overexpression of VEGF serves that purpose through angiogenesis. VEGF family has five members such as VEGF-A, VEGF-B, VEGF-C, VEGF-D, and Placenta Growth Factor (PGF). Of the aforementioned growth factors, VEGF-A is responsible for angiogenesis and the processes associated with endothelial cells. VEGF-A binds to VEGF receptors on the endothelial cells, which triggers a tyrosine kinase pathway leading to angiogenesis. VEGF-A has been found to be associated with poor prognosis in various cancers, diabetic retinopathy, and age-related macular degeneration. Therapeutic agents are developed to inhibit the transduction pathways of vascular endothelial growth factor. Drugs such as monoclonal antibodies against VEGF and tyrosine kinase inhibitors are known to inhibit the angiogenesis process and disease progression.
Global VEGF Antibodies Market – Drivers & Restraints
Rising prevalence of diseases, such as cancer and macular degeneration, is a pivotal factor expected to boost the growth of the global VEGF antibodies market over the forecast period. According to a report released by the American Cancer Society in 2017, cancer was pronounced as the second most common cause of death in the U.S., which accounts for at least one out of every four deaths. Novel therapies such as monoclonal antibodies and angiogenesis inhibitors are highly specialized targeted therapies, which directly targets the cancerous cells. The preference for targeted therapies is rising, owing to the advantages (lesser side effects) offered by targeted therapies over conventional therapies such as chemotherapy. Furthermore, robust pipeline of VEGF antibodies is expected to boost the market growth over the forecast period. For instance, Brolucizumab (Alcon) is in phase 3 clinical trials, Abicipar (Allergan Plc) is in phase 3 trials, and RG7716 (Genentech) is in phase 2 trials, all indicated for age-related macular degeneration.
LIMITED TIME OFFER – Hurry Up!
Get Discount For Buyers UPTO 25% OFF On Any Research Report
Apply Promo Code “CHRISTMAS2020” And Get Instant Discount Of USD 1000
Buy Now This Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/1614
Moreover, Tecentriq manufactured by Roche received the U.S. FDA priority review status to treat people with metastatic non-squamous non-small cell lung cancer in May 2018. Therapies already present in the market have shown improved clinical outcome in cancer as well as age-related macular degeneration (AMD). For instance, Lucentis, as well as Avastin have shown significant improvement in medical outcomes in associated indications such as cancer. These therapies have spurred the interest of manufacturers to further carry out research in this category, which is shown in terms of number of agents present in the pipeline. Blockbuster drugs such as Avastin and Lucentis allow manufacturers to invest in research and development of such therapies, in order to generate the revenues later on while providing the benefits to patients as well. These factors are predicted to foster the global market growth in the foreseeable future.
On the contrary, high costs of these medications, biosimilar research, and subsequent product launches are expected to hamper the growth of the global VEGF antibodies market. The U.S. Food & Drug Administration has already approved Mvasi (bevacizumab-awwb), a biosimilar to Avastin (bevacizumab) in December 2017. Moreover, the European Commission approved the biosimilar to Avastin (bevacizumab) in January 2018.
Global VEGF Antibodies Market – Regional Insights
North America holds the significant presence of leading manufacturers, who are indulged in exclusive research and development of various therapies. Manufacturers such as Novartis (Europe) and Genentech currently have these therapies in the pipeline and are soon likely to enter the global market. Moreover, insurance facilities are expected to drive growth of the market in North America.
The Asia Pacific region is expected to showcase moderate market growth, owing to high costs of these therapies and fairly low availability overall the region. Sophisticated insurance facilities, such as Medicaid and Medicare, are not present in the developing economies of the world, due to which patients cannot afford costly medical treatment in these regions.
Get PDF Research Brochure for more Professional and Technical Insights: https://www.coherentmarketinsights.com/insight/request-sample/1614
Global VEGF Antibodies Market – Key Players
The leading players operating in the global vascular endothelial growth factor (VEGF) antibodies market include Genentech, Inc., Novartis, Exelixis, Inc., Eli Lilly and Company, Bayer Pharma AG, Regeneron Pharmaceuticals, Inc., Valeant Pharmaceuticals, Ceres Oncology Pty Ltd., and ThromboGenics, Inc.
By Drug Type,
By Route of Administration,
By Distribution Channel,
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies
- North America
- Asia Pacific
- Latin America
- Middle East
Other Exclusive Reports:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
- CDN Newswire